Biotech 360°

Investing in the future of biotech

The biotech sector is at an inflection point, whereas the convergence of technology and science will bring more innovative, targeted, more cost-efficient, and faster-developed therapies to the market.

Theme Description

The biotech sector is at an inflection point, whereas the convergence of technology and science will bring more innovative, targeted, more cost-efficient, and faster-developed therapies to the market.

We capture this industry evolution with a strategy whose investments span throughout the entire value chain of drug development and not only limited to drug developers. The strategy focuses on tomorrow's new generation of tools & diagnostics techs, drugs, and life science services that could revolutionize the future of patient care. Such technologies include genetic medicines, cell therapy and liquid  biopsy.  The goal is precision medicine by which more efficient targeted therapies could reduce healthcare spending and possibly trigger a value-based industry. Artificial Intelligence will become key in molecule modeling.

Accurate diagnostic platforms render precision treatments possible while complex drugs will be increasingly manufactured by specialized outsourcing service companies.  The strategy invests in companies with robust and versatile technology platforms, which could disrupt massive markets such as cardiovascular, central nervous system and oncology, or address unique unmet medical needs such as orphan diseases.

Performances
All Time High All Time Low
PRICE: 214.07 DATE: 09-Aug-2021 PRICE: 73.44 DATE: 02-Jan-2017
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec annual
2022 -21.99% -3.16% -0.55% -17.21% -5.95% 5.44% -38.31%
2021 5.86% -3.54% -8.86% 8.60% -1.97% 10.03% 1.15% 1.01% -3.71% -0.35% -6.00% -5.74% -5.31%
2020 -3.40% -0.26% -11.30% 21.98% 8.96% 0.87% 0.31% -0.45% 4.20% -3.65% 13.46% 1.99% 32.91%
2019 15.80% 11.57% 0.26% -8.19% -4.73% 7.44% -3.43% -9.00% -4.91% 2.49% 15.87% 3.53% 25.04%
2018 11.25% -3.05% 2.15% -2.46% 3.85% -4.21% -0.18% 7.42% 0.32% -17.52% 5.92% -12.25% -11.84%
2017 10.54% 7.92% 5.85% 2.82% -4.04% 7.64% 3.43% 13.61% 2.96% -2.04% 3.70% 0.41% 65.52%
2016 -16.36% -0.86% 7.62% 2.50% 7.54% -13.80% 9.19% -0.82% 6.42% -16.60% 1.01% -10.70% -26.48%
2015 -3.81% -0.03% 9.64% -1.11% 6.69% -3.97% -14.19% -7.45% 16.92% 1.23% 0.39%
All Time High All Time Low
PRICE: 195.71 DATE: 09-Aug-2021 PRICE: 80.97 DATE: 11-May-2022
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec annual
2022 -22.01% -3.23% -0.50% -17.27% -6.01% 5.53% -38.38%
2021 5.09% -3.98% -8.78% 8.91% -1.98% 9.78% 0.91% 0.41% -3.68% -0.34% -6.05% -5.67% -7.02%
2020 -3.79% 0.13% -11.15% 21.30% 8.03% 0.83% -0.45% -0.41% 3.38% -3.37% 13.18% 0.57% 27.48%
2019 6.13% 2.96% 15.59% 3.71% 30.98%
All Time High All Time Low
PRICE: 163.8 DATE: 09-Aug-2021 PRICE: 67.27 DATE: 11-May-2022
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec annual
2022 -21.67% -2.89% -0.74% -17.25% -6.26% 5.60% -38.16%
2021 5.49% -4.67% -7.94% 10.48% -1.61% 9.44% 1.35% -0.18% -3.74% -0.80% -5.37% -6.50% -5.87%
2020 0.03% -3.27% -8.70% 19.19% 7.73% 1.00% 2.16% -2.03% 0.73% -2.90% 14.75% -0.12% 28.56%
2019 12.80% 7.57% -2.19% -4.54% -6.10% 6.12% -4.47% -9.05% -3.40% 0.66% 12.83% 3.91% 11.81%
2018 5.08% -4.90% 0.09% 0.16% 4.18% 2.72% 0.73% 6.88% 2.03% -12.52% 3.52% -9.07% -3.01%
2017 -2.41% 0.54% -1.26% 1.10% -2.05%
Statistics
data as of 29-Jun-2022
reference index ARCA Biotechnology (USD)
data as of 29-Jun-2022
reference index ARCA Biotechnology (USD)
data as of 29-Jun-2022
reference index ARCA Biotechnology (USD)
Characteristics
  • currency USD
  • isin CH0275762380
  • number of holdings 29
  • management fees 1.3%
  • cut-off time 13:00:00
  • risk scale 6*
  • TICKER
  • TRADE DATE T
*The actual risk can vary significantly if you cash in at an early stage and you may get back less. You may not be able to sell your product easily or you may have to sell at a price that significantly impacts on how much you get back
  • currency USD
  • isin XS1668108928
  • bloomberg ticker JMLNARBT
  • number of holdings 29
  • management fees 1.3%
  • performance fees 15%
  • cut-off time 13:00:00
  • risk scale 5*
  • TICKER JMLNARBT
  • TRADE DATE T
*The actual risk can vary significantly if you cash in at an early stage and you may get back less. You may not be able to sell your product easily or you may have to sell at a price that significantly impacts on how much you get back
  • currency USD
  • isin XS1365787826
  • bloomberg ticker NXSRHEMA
  • number of holdings 29
  • management fees 1.4%
  • performance fees 12.72%
  • cut-off time 13:00:00
  • risk scale 5*
  • TICKER NXSRHEMA
  • TRADE DATE T
*The actual risk can vary significantly if you cash in at an early stage and you may get back less. You may not be able to sell your product easily or you may have to sell at a price that significantly impacts on how much you get back
Holdings & Breakdowns
GEOGRAPHICAL BREAKDOWN
INDUSTRY EXPOSURE

Data as of 29-Jun-2022

GEOGRAPHICAL BREAKDOWN
INDUSTRY EXPOSURE

Data as of 29-Jun-2022

GEOGRAPHICAL BREAKDOWN
INDUSTRY EXPOSURE

Data as of 29-Jun-2022

Show all
Asset class EQUITY
Inception date 23-Mar-2015
Currency USD
ISIN CH0275762380
Issue price 100
Last price 104.56
Factsheet Termsheet
PRICE: 29-Jun-2022 104.56
YTD performance -38.31 %
Asset class EQUITY
Inception date 11-Sep-2019
Currency USD
ISIN XS1668108928
Ticker JMLNARBT
Issue price 100
Last price 95.66
Factsheet Termsheet
PRICE: 29-Jun-2022 95.66
YTD performance -38.38 %
Asset class EQUITY
Inception date 14-Sep-2017
Currency USD
ISIN XS1365787826
Ticker NXSRHEMA
Issue price 100
Last price 79.49
Factsheet Termsheet
PRICE: 29-Jun-2022 79.49
YTD performance -38.16 %
Contact